Cadherins as cancer biomarkers
AssigneeThe General Hospital Corporation
InventorsShyamala Maheswaran, David Tsai Ting, Daniel A. Haber
Life of this patent
Estimating the term…
Abstract
Methods of isolating, enriching, capturing, identifying, or detecting the presence of, cancerous cells in a sample, e.g., a blood sample from a subject, by detecting the presence of one or more cancer cell surface markers selected from the group consisting of cadherin 1 (CDH1), CDH2, CDH3, CDH4, CDH5, CDH9, CDH11, CDH17, CDH19, protocadherin 9 (PCDH9) and/or PCDH beta 13 (PCDHb13), and optionally an additional cancer cell surface marker, e.g., EpCAM, MUC1, EphB4, EGFR, CEA, and/or HER2.
Claims16
A device for separation of cells in a sample, the device comprising an inlet, an outlet, and one or more areas coated with agents that bind to each of cancer cell surface markers cadherin 1 (CDH1), CDH2, CDH3, CDH4, CDH5, CDH9, CDH11, CDH17, CDH19, protocadherin 9 (PCDH9) and PCDH beta 13 (PCDHb13), configured to separate cells that express the cancer cell surface markers from cells that do not express the cancer cell surface markers.
A device for separation of cells in a sample, the device comprising an inlet, an outlet, and magnetic beads, wherein the magnetic beads are coated with agents that bind to each of cancer cell surface markers cadherin 1 (CDH1), CDH2, CDH3, CDH4, CDH5, CDH9, CDH11, CDH17, CDH19, protocadherin 9 (PCDH9) and PCDH beta 13 (PCDHb13), wherein the device is configured to separate cells that express the cancer cell surface markers from cells that do not express the cancer cell surface markers.
Dependencies are inferred from the claim text.